Management of relapsing-remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

Journal of the Neurological Sciences

Volumn 339, Issue 1-2, 2014, Pages 196-206

  Correale, Jorge ^a   Abad, Patricio ^b   Alvarenga, Regina ^c   Alves Leon, Soniza ^d   Armas, Elizabeth ^e   Barahona, Jorge ^f   Buzó, Ricardo ^g   Corona, Teresa ^h   Cristiano, Edgardo ⁱ   Gracia, Fernando ^j   Bonitto, Juan García ^k   Macías, Miguel Angel ^l   Soto, Arnoldo ^m   Vizcarra, Darwin ⁿ   Freedman, Mark S ^o  

^a FLENI   (Argentina)

^b HOSPITAL METROPOLITANO   (Ecuador)

^c HOSPITAL DA LAGOA   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^f UNIVERSIDAD DEL DESARROLLO   (Chile)

^g HOSPITAL DE CLÍNICAS   (Uruguay)

^h NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

ⁱ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^j Medicine and Health Sciences   (United States)

^k Servicio de Neurología Clinica de Marly and Entidad Prestadora de Servicios de Salud Nogales   (Colombia)

^l Departamento de Neurociencias CUCS UdeG   (Mexico)

^m Centro Medico Docente La Trinidad   (Venezuela)

ⁿ HOSPITAL NACIONAL CAYETANO HEREDIA   (Peru)

^o OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Algorithm; Clinical recommendations; Disability; Latin America; MRI; Multiple sclerosis; Relapses; Treatment

Indexed keywords

ACTIVATED CARBON; ALEMTUZUMAB; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; COLESTYRAMINE; CYCLOPHOSPHAMIDE; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; DISOPYRAMIDE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GADOLINIUM; GLATIRAMER; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; OCRELIZUMAB; QUINIDINE; SOTALOL; STEROID; TERIFLUNOMIDE; VITAMIN D; IMMUNOSUPPRESSIVE AGENT;

ALTERNATIVE MEDICINE; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN ATROPHY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COGNITION; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; EXERCISE TEST; EXPANDED DISABILITY STATUS SCALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RELAPSE; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SEROCONVERSION; SOUTH AND CENTRAL AMERICA; STEROID THERAPY; SYSTEMATIC REVIEW; TIMED 25 FOOT WALK; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; WALKING; DISEASE MANAGEMENT; EPIDEMIOLOGY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRACTICE GUIDELINE; STANDARDS;

DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LATIN AMERICA; MITOXANTRONE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VITAMIN D;

EID: 84898057394     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2014.02.017     Document Type: Article

References (176)

1. M.S. Freedman, D. Selchen, D.L. Arnold, A. Prat, B. Banwell, and M. Yeung et al. Treatment optimization in MS: Canadian MS working group updated recommendations Can J Neurol Sci 40 2013 307 323
2. P. Abad, J. Nogales-Gaete, V. Rivera, E. Cristiano, F. Hamuy, and C. Oehninger et al. LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants Rev Neurol 55 2012 737 748
3. A. Carrá, M.Á. Macías-Islas, A.A. Gabbai, J. Correale, C. Bolaña, and E.D. Sotelo et al. Optimizing outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America Ther Adv Neurol Disord 4 2011 349 360
4. A. García Merino, O. Fernández, X. Montalbán, C. de Andrés, and T. Arbizu Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy Neurologia 25 2010 378 390
5. D. Laplaud, E. Bodiguel, C. Bensa, F. Blanc, D. Brassat, and L. Magy et al. Recommendations for the management of multiple sclerosis relapses Rev Neurol (Paris) 168 2012 425 433
6. E. Cristiano, J. Rojas, M. Romano, N. Frider, G. Machnicki, and D. Giunta et al. The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review Mult Scler 19 2013 844 854
7. P. Abad, M. Perez, E. Castro, T. Alarcón, R. Santibáñ ez, and F. Díaz Prevalence of multiple sclerosis in Ecuador Neurologia 25 2010 309 313
8. M.O. Melcon, L. Gold, A. Carrá, F. Cáceres, J. Correale, and E. Cristiano et al. Argentine Patagonia: prevalence and clinical features of multiple sclerosis Mult Scler 14 2008 656 662
9. E. Cristiano, L. Patrucco, J.I. Rojas, F. Cáceres, A. Carrá, and J. Correale et al. Prevalence of multiple sclerosis in Buenos Aires, Argentina using the capture-recapture method Eur J Neurol 16 2009 183 187
10. C. Ketzoian, C. Oehninger, and J. Alcántaran Estudio de la prevalencia de la sclerosis múltiple en Uruguay Acta Neurol Col 15 1999 6
11. G. Luetic MS in Latin America Int MS J 15 2008 6 11
12. O. Gonzalez, and J. Sotelo Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 59 1995 528 530
13. D. Callegaro, C.A. de Lolio, J. Radvany, C.P. Tilbery, R.A. Mendonça, and A.C. Melo Prevalence of multiple sclerosis in the city of São Paulo, Brazil, in 1990 Neuroepidemiology 11 1992 11 14
14. D. Callegaro, M. Goldbaum, L. Morais, C.P. Tilbery, M.A. Moreira, and Gabbai et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, in 1997 Acta Neurol Scand 104 2001 208 213
15. T. Corona, and G.C. Román Multiple sclerosis in Latin America Neuroepidemiology 26 2006 1 3
16. V.M. Rivera, and J.A. Cabrera Avance de la esclerosis múltiple en Latinoamérica Médico Interam 19 2000 458 465
17. C. Alvarado-de la Barrera, J. Zúñiga-Ramos, J.A. Ruiz-Morales, B. Estañol, J. Granados, and L. Llorente HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis Neurology 55 2000 1897 1990
18. D.D. Kostyu, and D.B. Amos Mysteries of the Amerindians Tissue Antigens 17 1981 111 123
19. J. Flores, S. González, X. Morales, P. Yescas, A. Ochoa, and T. Corona Absence of multiple sclerosis and demyelinating diseases among Lacandonians, a pure Amerindian ethnic group in México Mult Scler Int 2012 2012 292631
20. C. Gorodezky, L.E. Castro-Escobar, and A. Escobar-Gutiérrez The HLA system in the prevalent Mexican Indian group: the Nahuas Tissue Antigens 25 1985 38 46
21. S.M. Mirsattari, J.B. Johnston, R. McKenna, M.R. Del Bigio, P. Orr, and R.T. Ross et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica Neurology 56 2001 317 323
22. J. Kira Multiple sclerosis in the Japanese population Lancet Neurol 2 2003 117 127
23. O.L. Rojas, A. Rojas-Villarraga, P. Cruz-Tapias, J.L. Sánchez, J.C. Suárez-Escudero, and M.A. Patarroyo et al. HLA class II polymorphism in Latin American patients with multiple sclerosis Autoimmun Rev 9 2010 407 413
24. T. Masterman, A. Ligers, T. Olsson, M. Andersson, O. Olerup, and J. Hillert HLA-DR15 is associated with lower age at onset in multiple sclerosis Ann Neurol 48 2000 211 219
25. L. Handunnetthi, S.V. Ramagopalan, and G.C. Ebers Multiple sclerosis, vitamin D, and HLA-DRB1*15 Neurology 74 2010 1905 1910
26. E. Quelvennec, O. Bera, P. Cabre, M. Alizadeh, D. Smadja, and F. Jugde et al. Genetic and functional studies in multiple sclerosis patients from Martinique attest for a specific and direct role of the HLA-DR locus in the syndrome Tissue Antigens 61 2003 166 171
27. S.V. Alves-Leon, R. Papais-Alvarenga, M. Magalhães, M. Alvarenga, L.C. Thuler, and O. Fernández y Fernandez Ethnicity-dependent association of HLA DRB1-DQA1-DQB1 alleles in Brazilian multiple sclerosis patients Acta Neurol Scand 115 2007 306 311
28. J.O. Fleming, and T.D. Cook Multiple sclerosis and the hygiene hypothesis Neurology 67 2006 2085 2086
29. J. Correale, and M. Farez Parasite infections modulate the immune response in multiple sclerosis Ann Neurol 61 2007 97 108
30. J. Correale MS in Latin America Int MS J 15 2008 3 5
31. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Ann Neurol 58 2005 840 846
32. C.H. Polman, S.C. Reingold, B. Banwell, M. Clanet, J.A. Cohen, and M. Filippi et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria Ann Neurol 69 2011 292 302
33. D.H. Miller, B.G. Weinshenker, M. Filippi, B.L. Banwell, J.A. Cohen, and M.S. Freedman et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach Mult Scler 14 2008 1157 1174
34. A.J. Solomon, E.P. Klein, and D. Bourdette "Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS Neurology 78 2012 1986 1991
35. J.I. Rojas, L. Patrucco, and E. Cristiano Multiple sclerosis in Argentina. Systematic review and meta-analysis Med (B Aires) 72 2012 449 454
36. W.O. Arruda, R.H. Scola, H.A. Teive, and L.C. Werneck Multiple sclerosis: report on 200 cases from Curitiba, Southern Brazil and comparison with other Brazilian series Arq Neuropsiquiatr 59 2001 165 170
37. E. Cardoso, T. Fukuda, J. Pereira, J. Seixas, R. Miranda, and B. Rodrigues et al. Clinical and epidemiological profile of multiple sclerosis in a reference center in the State of Bahia, Brazil Arq Neuropsiquiatr 64 2006 727 730
38. I. Bostrom, L. Stawiarz, and A.M. Landtblom Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg) Mult Scler 19 2013 46 52
39. S.M. Orton, B.M. Herrera, I.M. Yee, W. Valdar, S.V. Ramagopalan, and A.D. Sadovnick et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study Lancet Neurol 5 2006 932 936
40. E. Ojeda, D. Diaz-Cortes, D. Rosales, C. Duarte-Rey, J.M. Anaya, and A. Rojas-Villarraga Prevalence and clinical features of multiple sclerosis in Latin America Clin Neurol Neurosurg 115 2013 381 387
41. M.A. Lana-Peixoto, E.R. Frota, G.B. Campos, and L.P. Monteiro Brazilian committee for treatment and research in multiple sclerosis Arq Neuropsiquiatr 70 2012 102 107
42. C. Arberas, F. Cáceres, N. Fernández-Liguori, L. Saladino, and V. Romanin Formas familiares de esclerosis multiple en una cohorte de pacientes en la Republica Argentina Rev Neurol 43 2006 15
43. A. Paolillo, C. Pozzilli, E. Giugni, V. Tomassini, C. Gasperini, and M. Fiorelli et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta Eur J Neurol 9 2002 645 655
44. D. Bates Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials Neurology 76 1 Suppl. 1 2011 S14 S25
45. European Study Group on interferon beta-1b in secondary progressive MS Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis Lancet 352 1998 1491 1497
46. H. Panitch, A. Miller, D. Paty, and B. Weinshenker North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study Neurology 63 2004 1788 1795
47. L. La Mantia, L.M. Munari, and R. Lovati Glatiramer acetate for multiple sclerosis Cochrane Database Syst Rev 5 May 12 2010 [CD004678]
48. M.S. Freedman Multiple sclerosis therapeutic strategies: use second-line agents as first-line agents when time is of the essence Neurol Clin Pract 1 2011 66 68
49. O. Garcea, A. Villa, F. Caceres, T. Adoni, M. AlegrIa, and T.R. Barbosa et al. Early treatment of multiple sclerosis: a Latin American Experts Meeting Mult Scler 15 2009 S1 S12 [Suppl.]
50. A.T. Reder, G.C. Ebers, A. Traboulsee, D. Li, D. Langdon, and D.S. Goodin et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS Neurology 74 2010 1877 1885
51. R.A. Bermel, B. Weinstock-Guttman, D. Bourdette, P. Foulds, X. You, and R.A. Rudick Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study Mult Scler 16 2010 588 596
52. C. Ford, A.D. Goodman, K. Johnson, N. Kachuck, J.W. Lindsey, and R. Lisak et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate Mult Scler 16 2010 342 350
53. A. Shirani, Y. Zhao, M.E. Karim, C. Evans, E. Kingwell, and M.L. van der Kop et al. Interferon beta and long-term disability in multiple sclerosis JAMA Neurol 70 2013 651 652
54. G.C. Ebers, A. Traboulsee, D. Li, D. Langdon, A.T. Reder, and D.S. Goodin et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial J Neurol Neurosurg Psychiatry 81 2010 907 912
55. O. Katrych, T.M. Simone, S. Azad, and S.A. Mousa Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes CNS Neurol Disord Drug Targets 8 2009 512 519
56. R.P. Kinkel, M. Dontchev, C. Kollman, T.T. Skaramagas, P.W. O'Connor, and J.H. Simon et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance Arch Neurol 69 2012 183 190
57. L. Kappos, M.S. Freedman, C.H. Polman, G. Edan, H.P. Hartung, and D.H. Miller et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Lancet Neurol 8 2009 987 997
58. D.S. Goodin, J. Jones, D. Li, A. Traboulsee, A.T. Reder, and K. Beckmann et al. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS PLoS One 6 2011 e22444
59. B. Uitdehaag, C. Constantinescu, P. Cornelisse, D. Jeffery, L. Kappos, and D. Li et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study Ther Adv Neurol Disord 4 2011 3 14
60. C. Evans, J. Tam, E. Kingwell, and J. Oger University of British Columbia MS Clinic Neurologists, Tremlett H. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study Clin Ther 34 2012 341 350
61. A. Scalfari, A. Neuhaus, A. Degenhardt, G.P. Rice, P.A. Muraro, and M. Daumer et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability Brain 133 2010 1914 1929
62. C. Binquet, C. Quantin, G. Le Teuff, J.F. Pagliano, M. Abrahamowicz, and T. Moreau The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis Neuroepidemiology 27 2006 45 54
63. H. Tremlett, M. Yousefi, V. Devonshire, P. Rieckmann, and Y. Zhao UBC Neurologists. Impact of multiple sclerosis relapses on progression diminishes with time Neurology 73 2009 1616 1623
64. R. Bergamaschi, C. Berzuini, A. Romani, and V. Cosi Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis J Neurol Sci 189 2001 13 21
65. M.A. Leone, S. Bonissoni, L. Collimedaglia, F. Tesser, S. Calzoni, and A. Stecco et al. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study Mult Scler 14 2008 485 493
66. B. Runmarker, and O. Andersen Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up Brain 116 1993 117 134
67. A. Langer-Gould, R.A. Popat, S.M. Huang, K. Cobb, P. Fontoura, and M.K. Gould et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review Arch Neurol 63 2006 1686 1691
68. T.F. Scott, and C.J. Schramke Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later J Neurol Sci 292 2010 52 56
69. M. Vercellino, A. Romagnolo, A. Mattioda, S. Masera, C. Piacentino, and A. Merola et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants Acta Neurol Scand 119 2009 126 130
70. A. Scalfari, A. Neuhaus, M. Daumer, G.C. Ebers, and P.A. Muraro Age and disability accumulation in multiple sclerosis Neurology 77 2011 1246 1252
71. A. Damasceno, F. Von Glehn, C.O. Brandão, B.P. Damasceno, and F. Cendes Prognostic indicators for long-term disability in multiple sclerosis patients J Neurol Sci 324 2013 29 33
72. C.C. Ferreira Vasconcelos, G.A. Cruz Dos Santos, L.C. Thuler, S.M. Camargo, and R.M. Papais Alvarenga African ancestry is a predictor factor to secondary progression in clinical course of multiple sclerosis ISRN Neurol 2012 2012 410629
73. I. Kister, E. Chamot, J.H. Bacon, P.M. Niewczyk, R.A. De Guzman, and B. Apatoff et al. Rapid disease course in African Americans with multiple sclerosis Neurology 75 2010 217 223
74. S. Jeannin, R. Deschamps, N. Chausson, and P. Cabre Response to interferon-beta treatment in Afro-Caribbeans with multiple sclerosis Mult Scler Int 2011 2011 950126
75. S. Klineova, J. Nicholas, and A. Walker Response to disease modifying therapies in African Americans with multiple sclerosis Ethn Dis 22 2012 221 225
76. B.A. Cree, A. Al-Sabbagh, R. Bennett, and D. Goodin Response to interferon beta-1a treatment in African American multiple sclerosis patients Arch Neurol 62 2005 1681 1683
77. B.A. Cree, W.H. Stuart, C.S. Tornatore, D.R. Jeffery, A.l. Pace, and C.H. Cha et al. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data Arch Neurol 68 2011 464 468
78. O. Khan, B.A.C. Cree, P. Cabre, M. Inglese, J. Perumal, and X. Meng et al. The efficacy and safety of fingolimod in African-American patient subgroup from FREEDOMS II (abstract P522) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
79. J. Río, C. Nos, M. Tintoré, N. Téllez, I. Galán, and R. Pelayo et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients Ann Neurol 59 2006 344 352
80. V.C. Pereira, F.R. Malfetano, I.D. Meira, L.F. Souza, A.M. Liem, and A. Maiolino et al. Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort Arq Neuropsiquiatr 70 2012 774 779
81. H.L. Tremlett, and J. Oger Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS Neurology 61 2003 551 554
82. S.S. Jordy, C.P. Tilbery, and M.M. Fazzito Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases Arq Neuropsiquiatr 66 2008 11 14
83. Tde M. de Oliveira, A.P. Fiore, and Y.D. Fragoso Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience Patient Prefer Adher 2 2008 41 46
84. P. O'Connor, J.S. Wolinsky, C. Confavreux, G. Comi, L. Kappos, and T.P. Olsson et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 2011 1293 1303
85. A. Miller, L. Kappos, G. Comi, C. Confavreux, M. Freedman, and T. Olsson et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: Results from TOWER, a second, pivotal, phase 3 placebo-controlled study (S01.004) Presented at the 65th American Academy of Neurology annual meeting, San Diego CA, March 16-23 2013
86. P. Vermersch, A. Czlonkowska, L.M. Grimaldi, C. Confavreux, G. Comi, and L. Kappos et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial Mult Scler 2013 http://dx.doi.org/1177/1352458513507821 [epublished November 21]
87. L. Kappos, E.W. Radue, P. O'Connor, C. Polman, R. Hohlfeld, and P. Calabresi et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
88. P.A. Calabresi, D. Goodin, D. Jeffery, L. Kappos, F.D. Lublin, and K. Rammohan et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing-remitting multiple sclerosis (abstract P491) Presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2012 Lyons France [October 10-13]
89. J.A. Cohen, F. Barkhof, G. Comi, H.P. Hartung, B.O. Khatri, and X. Montalban et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
90. G. Comi, R. Gold, L. Kappos, P. Von Rosenstiel, A. Sinha, and D. Tomic Relapse and safety outcomes in patients who transitioned from glatiramer acetate or interferon beta to fingolimod in the open-label FIRST study (abstract P513) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
91. T. Spelman, N. Bergvall, D. Tomic, M. Trojano, G. Izquierdo, and A. Lugaresi et al. Real-world comparative effectiveness of fingolimod and interferon/glatiramer therapies in a switch population using propensity-matched data from MSBase (abstract P1096) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
92. C.H. Polman, P.W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, and D.H. Miller et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
93. C.S. Tan, and I.J. Koralnik Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis Lancet Neurol 9 2010 425 437
94. G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, and A. Natarajan et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 366 2012 1870 1880
95. L. Gorelik, M. Lerner, S. Bixler, M. Crossman, B. Schlain, and K. Simon et al. Anti-JC virus antibodies: implications for PML risk stratification Ann Neurol 68 2010 295 303
96. J.R. Berger, S.A. Houff, J. Gurwell, N. Vega, C.S. Miller, and R.J. Danaher JC virus antibody status underestimates infection rates Ann Neurol 74 2013 84 90
97. R. Lanzillo, R. Liuzzi, L. Amato, V. Vacchiano, M. Moccia, and G. Vacca et al. JC virus antibodies index on natalizumab treatment: fluctuations and seroconversion (abstract P599) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
98. M.I. Dominguez-Mozo, M. Garcia-Montojo, Heras V. De Las, A. Garcia-Martinez, A.M. Arias-Leal, and I. Casanova et al. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish multiple sclerosis patients treated with natalizumab J Neuroimmune Pharmacol 8 2013 1277 1286
99. C. Warnke, P. Markwerth, M. Pawlita, D. Hermsen, H.-P. Hartung, and M. Stettner et al. The anti-JC virus antibody index in CSF for diagnosis of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (abstract 181) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
100. E. Havrdova, S. Galetta, D. Stefoski, and G. Comi Freedom from disease activity in multiple sclerosis Neurology 74 Suppl. 3 2010 S3 S7
101. E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, and C.H. Polman et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study Lancet Neurol 8 2009 254 260
102. L. Kappos, E.-W. Radue, P. O'Connor, M. Amato, L. Zhang-Auberson, and D. Tang et al. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis: results from a phase 3, placebo-controlled study (FREEDOMS) (abstract PD6-002) Neurology 76 Suppl. 4 2011 A563
103. B. Khatri, F. Barkhof, G. Comi, J. Jin, G. Francis, and J. Cohen Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to IFN-b1a: results from a phase 3, active-controlled study (TRANSFORMS) Neurology 78 Suppl. 1 2012 D5.006
104. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
105. B.C. Healy, D. Engler, B. Glanz, A. Musallam, and T. Chitnis Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis Mult Scler Int 2013 2013 189624
106. S. Schwid Quantitative functional measures in MS: what is a reliable change? Neurology 58 2002 1294 1296
107. J. Río, C. Nos, M. Tintoré, C. Borrás, I. Galán, and M. Comabella et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials Ann Neurol 52 2002 400 406
108. M. Kaufman, D. Moyer, and J. Norton The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite Mult Scler 6 2000 286 290
109. J.S. Fischer, R.A. Rudick, G.R. Cutter, and S.C. Reingold The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcomes assessment Mult Scler 5 1999 244 250
110. L. Prosperini, V. Gallo, N. Petsas, G. Borriello, and C. Pozzilli One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis Eur J Neurol 16 2009 1202 1209
111. J. Río, A. Rovira, M. Tintoré, E. Huerga, C. Nos, and N. Tellez et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients Mult Scler 14 2008 479 484
112. C. Lukas, A. Minneboo, V. de Groot, B. Moraal, D.L. Knol, and C.H. Polman et al. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis J Neurol Neurosurg Psychiatry 81 2010 1351 1356
113. T. Korteweg, M. Rovaris, V. Neacsu, M. Filippi, G. Comi, and B.M. Uitdehaag et al. Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics? Mult Scler 15 2009 465 471
114. J. Río, J. Castilló, A. Rovira, M. Tintoré, J. Sastre-Garriga, and A. Horga et al. Measures in the first year of therapy predict the response to interferon beta in MS Mult Scler 15 2009 848 853
115. M.P. Sormani, J. Rio, M. Tintorè, A. Signori, D. Li, and P. Cornelisse et al. Scoring treatment response in patients with relapsing multiple sclerosis Mult Scler 19 2013 605 612
116. C. Potagas, E. Giogkaraki, G. Koutsis, D. Mandellos, E. Tsirempolou, and C. Sfagos et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes J Neurol Sci 267 2008 100 106
117. L. Feuillet, F. Reuter, B. Audoin, I. Malikova, K. Barrau, and A.A. Cherif et al. Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis Mult Scler 13 2007 124 127
118. R. Robles-Cedeño, E. Quintana, J. Gich, R. Menéndez, H. Perkal, and L. Martín et al. Clinical characterization and molecular biomarkers of a group of subjects with radiologically isolated syndrome (abstract P271) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
119. F. Cáceres, S. Vanotti, S. Rao, and RECONEM Workgroup Epidemiological characteristics of cognitive impairment of multiple sclerosis patients in a Latin American country J Clin Exp Neuropsychol 33 2011 1094 1098
120. J. Nogales-Gaete, R. Aracena, V. Díaz, P. Zitko, C. Eloiza, and S. Cepeda-Zumaeta et al. Neuropsychological assessment of patients with relapsing remitting multiple sclerosis prior to the use of immunomodulatory drugs Rev Med Chil 140 2012 1437 1444
121. J.H. Kalmar, E.A. Gaudino, N.B. Moore, J. Halper, and J. Deluca The relationship between cognitive deficits and everyday functional activities in multiple sclerosis Neuropsychology 22 2008 442 449
122. S.M. Rao, G.J. Leo, L. Ellington, T. Nauertz, L. Bernardin, and F. Unverzagt Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning Neurology 41 1991 692 696
123. S.M. Rao Cognitive Function Study Group of the National Multiple Sclerosis Society A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis 1990 Medical College of Wisconsin Milwaukee
124. R.H. Benedict, J.S. Fischer, C.J. Archibald, P.A. Arnett, W.W. Beatty, and J. Bobholz et al. Minimal neuropsychological assessment of MS patients: a consensus approach Clin Neuropsychol 16 2002 381 397
125. L. Strober, J. Englert, F. Munschauer, B. Weinstock-Guttman, S. Rao, and R.H. Benedict Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS Mult Scler 15 2009 1077 1084
126. P. Duque, J. Ibanez, A. Del Barco, J. Sepulcre, E. de Ramon, and O. Fernandez-Fernandez et al. Normalisation and validation of the Brief Neuropsychological Battery as the reference neuropsychological test in multiple sclerosis Rev Neurol 54 2012 263 270
127. J.B. Brooks, M.C. Borela, and Y.D. Fragoso Assessment of cognition using the Rao's Brief Repeatable Battery of Neuropsychological Tests on a group of Brazilian patients with multiple sclerosis Arq Neuropsiquiatr 69 2011 887 891
128. A. Smith Symbol Digit Modalities Test: manual 1982 Western Psychological Services Los Angeles CA
129. M. Calabrese, F. Agosta, F. Rinaldi, I. Mattisi, P. Grossi, and A. Favaretto et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis Arch Neurol 66 2009 1144 1150
130. P.A. Arnett, C.I. Higginson, W.D. Voss, W.I. Bender, J.M. Wurst, and J.M. Tippin Depressed mood in multiple sclerosis: relationship to capacity-demanding memory and attentional functioning Neuropsychology 13 1999 434 446
131. C. Heesen, K.H. Schulz, J. Fiehler, U. Von der Mark, C. Otte, and R. Jung et al. Correlates of cognitive dysfunction in multiple sclerosis Brain Behav Immun 24 2010 1148 1155
132. A.T. Beck, C.H. Ward, M. Mendelson, J. Mock, and J. Erbaugh Inventory for measuring depression Arch Gen Psychiatry 4 1961 561 571
133. Fatigue guidelines development panel of the multiple sclerosis council for clinical practice guidelines Fatigue and multiple sclerosis. Evidence-based management strategies for fatigue in multiple sclerosis 1998 Paralyzed Veterans of America Washington, DC
134. M.P. Amato, D. Langdon, X. Montalban, R.H. Benedict, J. DeLuca, and L.B. Krupp et al. Treatment of cognitive impairment in multiple sclerosis: position paper J Neurol 260 2013 1452 1468
135. R. Jungedal, M. Lundkvist, E. Engdahl, R. Ramanujam, H. Westerlind, and A. Sominanda et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice Mult Scler 18 2012 1775 1781
136. L. Kappos, M. Clanet, M. Sandberg-Wollheim, E.W. Radue, H.P. Hartung, and R. Hohlfeld et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study Neurology 65 2005 40 47
137. P.S. Sorensen, C. Ross, K.M. Clemmesen, K. Bendtzen, J.L. Frederiksen, and K. Jensen et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191
138. H. Hegen, M. Schleiser, C. Gneiss, F. Di Pauli, R. Ehling, and B. Kuenz et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation Mult Scler 18 2012 610 615
139. P.S. Sorensen, N. Koch-Henriksen, C. Ross, K.M. Clemmesen, and K. Bendtzen Danish Multiple Sclerosis Study Group. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology 65 2005 33 39
140. P.A. Calabresi, G. Giovannoni, C. Confavreux, S.L. Galetta, E. Havrdova, and M. Hutchinson et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL Neurology 69 2007 1391 1403
141. J. Correale, M.C. Ysrraelit, and M.I. Gaitán Vitamin D-mediated immune regulation in multiple sclerosis J Neurol Sci 311 2011 23 31
142. K.L. Munger, L.I. Levin, B.W. Hollis, N.S. Howard, and A. Ascherio Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis JAMA 296 2006 2832 2838
143. J. Kragt, B. van Amerongen, J. Killestein, C. Dijkstra, B. Uitdehaag, and C.H. Polman et al. Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women Mult Scler 15 2009 9 15
144. H. Tremlett, I.A. van der Mei, F. Pittas, L. Blizzard, G. Paley, and D. Mesaros et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis Neuroepidemiology 31 2008 271 279
145. M. D'hooghe, P. Haentjens, G. Nagels, M. Garmyn, and J. De Keyser Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis Mult Scler 18 2012 451 459
146. J. Smolders, P. Menheere, A. Kessels, J. Damoiseaux, and R. Hupperts Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis Mult Scler 14 2008 1220 1224
147. S. Simpson, B. Taylor, L. Blizzard, A.L. Ponsonby, F. Pittas, and H. Tremlett et al. Higher levels of serum 25-hydroxyvitamin D3 are associated with a reduced risk of relapse in multiple sclerosis Ann Neurol 68 2010 193 203
148. E.M. Mowry, E. Waubant, C.E. McCulloch, D.T. Okuda, A.A. Evangelista, and R.R. Lincoln et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis Ann Neurol 72 2012 234 240
149. M.S. Stein, Y. Liu, O.M. Gray, J.E. Baker, S.C. Kolbe, and M.R. Ditchfield et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis Neurology 77 2011 1611 1618
150. M.T. Kampman, L.H. Steffensen, S.I. Mellgren, and L. Jørgensen Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial Mult Scler 18 2012 1144 1151
151. M. Soilu-Hanninen, J. Aivo, B.M. Lindstrom, I. Elovaara, M.L. Sumelahti, and M. Färkkilä et al. A randomised, double blind, placebo controlled
152. D.L. Rotstein, B.C. Healy, M.T. Malik, P. Kivisakk, B. Glanz, and T. Chitnis The effect of vitamin D on disease activity in multiple sclerosis patients on fingolimod (abstract P419) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
153. T. Holmøy, O. Torkildsen, K.M. Myhr, and K.I. Løken-Amsrud Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore Acta Neurol Scand Suppl 195 2012 63 69
154. R.M. Lucas, A.L. Ponsonby, K. Dear, P.C. Valery, M.P. Pender, and B.V. Taylor et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination Neurology 76 2011 540 548
155. T. Castillo-Trivino, E.M. Mowry, A. Gajofatto, D. Chabas, E. Crabtree-Hartman, and B.A. Cree et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy PLoS One 6 2011 e16664
156. N. Putzki, O. Yaldizli, M. Mäurer, S. Cursiefen, S. Kuckert, and C. Klawe et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries Eur J Neurol 17 2010 31 37
157. N. Bergvall, C. Makin, R. Lahoz, N. Agashivala, A. Pradhan, and G. Capkun et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis Curr Med Res Opin 29 2013 1647 1656
158. E. Fogarty, S. Schmitz, C. Walsh, N. Tubridy, and M. Barry Which drugs are most effective for relapsing remitting multiple sclerosis? A network meta analysis of disease modifying therapies (abstract P628) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
159. S. Braune, M. Lang, A. Bergmann, and NTC Study Group Second line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort J Neurol 260 2013 2981 2985
160. P.S. Sørensen, A. Bertolotto, G. Edan, G. Giovannoni, R. Gold, and E. Havrdova et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab Mult Scler 18 2012 143 152
161. N. Schwab, T. Schneider-Hohendorf, V. Posevitz, J. Breuer, K. Göbel, and S. Windhagen et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients Neurology 81 2013 865 871
162. P.W. O'Connor, A. Goodman, L. Kappos, F.D. Lublin, D.H. Miller, and C. Polman et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis Neurology 76 2011 1858 1865
163. M. Melis, E. Cocco, J. Frau, L. Lorefice, G. Fenu, and G. Coghe et al. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up Neurol Sci 35 2014 401 408
164. M.M. Vellinga, J.A. Castelijns, F. Barkhof, B.M. Uitdehaag, and C.H. Polman Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 13 Pt 2 2008 1150 1151
165. A. Kerbrat, E. Le Page, E. Leray, T. Anani, M. Coustans, and C. Desormeaux et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients J Neurol Sci 308 2011 98 102
166. O. Stüve, P.D. Cravens, E.M. Frohman, J.T. Phillips, G.M. Remington, and G. von Geldern et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology 72 2009 396 401
167. A. Miravalle, R. Jensen, and R.P. Kinkel Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy Arch Neurol 68 2011 186 191
168. Aubagio (teriflunomide) product monograph NDA 202992 - Food and Drug Administration approved labeling, September 12 2012
169. M. Cohen, E. Maillart, C. Papeix, S. Vukusic, D. Brassat, and J. De Sèze et al. Switching from natalizumab to fingolimod: risk of disease reactivation during the washout period is due to the previous activity of the disease. Follow-up of the ENIGM survey (abstract P623) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
170. M.J. Messina, M. Rodegher, D. Baroncini, M.A. Rocca, M. Filippi, and S. Maida et al. Can fingolimod treatment influence disease progression after natalizumab discontinuation? (abstract P621) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
171. J. Havla, B. Tackenberg, K. Hellwig, I. Meinl, M. Krumbholz, and F. Seitz et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis J Neurol 260 2013 1382 1387
172. J. de Seze, J. Ongagna, C. Zaenker, S. Courtois, N. Collongues, and M. Fleury et al. Reduction of washout delay between Tysabri and Gilenya: a regional real-life study (abstract P634) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
173. V.G. Jokubaitis, V. Li, T. Kalincik, G. Izquierdo, S. Hodgkinson, and R. Alroughani et al. Does switching to fingolimod from natalizumab result in short-term relapse exacerbation? (abstract 179) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
174. M.M. Paz Soldan, M. Novotna, D.J. Crusan, E.J. Atkinson, and O.H. Kantarci Pre- and post-progression relapses impact disability in progressive multiple sclerosis (abstract 199) Presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, Denmark, October 2-5 2013
175. L. La Mantia, L. Vacchi, C. Di Pietrantonj, G. Ebers, M. Rovaris, and S. Fredrikson et al. Interferon beta for secondary progressive multiple sclerosis Cochrane Database Syst Rev 1 Jan 18 2012 CD005181
176. G. Suarez-Kurtz Pharmacogenomics in admixed populations Trends Pharmacol Sci 26 2005 196 201